)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Nanexa
Nanexa (NANEXA) investor relations material
Nanexa Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary19 Feb, 2026
Executive summary
Secured a major license and option agreement with Moderna for PharmaShell®-based products, including an initial USD 3 million payment and potential milestones up to USD 500 million plus royalties.
Transitioned focus in NEX-22 project from liraglutide to semaglutide, targeting monthly and quarterly dosing for type 2 diabetes and obesity.
Achieved finalist status in the Fierce Life Sciences Innovation Awards for drug delivery technology.
Announced breakthrough preclinical data for monthly semaglutide formulation post-period.
Financial highlights
Q4 2025 turnover: SEK 30,090 thousand (up from SEK 4,517 thousand YoY), with SEK 27,999 thousand from Moderna agreement.
Q4 2025 EBIT: SEK 16,665 thousand (vs. -12,025 thousand YoY); profit after tax: SEK 16,036 thousand (vs. -11,631 thousand YoY).
FY 2025 turnover: SEK 36,149 thousand (up from SEK 24,361 thousand YoY); EBIT: SEK -8,768 thousand (vs. -26,062 thousand YoY); net loss: SEK -11,388 thousand (vs. -24,905 thousand YoY).
Cash and cash equivalents at year-end: SEK 44,567 thousand (vs. SEK 10,292 thousand YoY).
Cash flow for the year: SEK 34,276 thousand (vs. -54,877 thousand YoY).
Outlook and guidance
Board believes current working capital and cash are sufficient to finance operations until early 2027.
Focus remains on securing further revenue from pharma agreements and advancing business development, especially for semaglutide and GLP-1 projects.
No dividend proposed for 2025.
What is the scope of the Moderna collaboration?
How does PharmaShell mitigate GLP-1 side effects?
What is the plan for post-early 2027 funding?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nanexa
- Major partnership extended, patent granted, and funding secured amid revenue decline.NANEXA
Q3 20256 Nov 2025 - NEX-22 Phase I results support once-monthly dosing; financials show extended runway to Q1 2026.NANEXAQ2 202527 Aug 2025
- NEX-22 Phase I completed; cost savings improved results, but new funding is needed.NANEXAQ3 202413 Jun 2025
- NEX-22 clinical trial launched; losses narrowed, but new funding required within a year.NANEXAQ2 202413 Jun 2025
- NEX-22 clinical progress and new financing position Nanexa for growth despite Q1 losses.NANEXAQ1 20256 Jun 2025
- Positive NEX-22 clinical results and new financing position Nanexa for 2025 growth.NANEXAQ4 20245 Jun 2025
Next Nanexa earnings date
Q1 202629 Apr, 2026
Nanexa
Next Nanexa earnings date
Q1 202629 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage